PMID- 35410559
OWN - NLM
STAT- MEDLINE
DCOM- 20220525
LR  - 20220525
IS  - 1744-7674 (Electronic)
IS  - 1354-3776 (Linking)
VI  - 32
IP  - 6
DP  - 2022 Jun
TI  - Soluble epoxide hydrolase inhibitors: an overview and patent review from the last 
      decade.
PG  - 629-647
LID - 10.1080/13543776.2022.2054329 [doi]
AB  - INTRODUCTION: Biological effects mediated by the CYP450 arm of arachidonate 
      cascade implicate the enzyme-soluble epoxide hydrolase (sEH) in hydrolyzing 
      anti-inflammatory epoxy fatty acids to pro-inflammatory diols. Hence, inhibiting 
      the sEH offers a therapeutic approach to treating inflammatory diseases. Over 
      three decades of work has shown the role of sEH inhibitors (sEHis) in treating 
      various disorders in rodents and larger veterinary subjects. Novel chemical 
      strategies to enhance the efficacy of sEHi have now appeared. AREAS COVERED: A 
      comprehensive review of patent literature related to soluble epoxide hydrolase 
      inhibitors in the last decade (2010-2021) is provided. EXPERT OPINION: Soluble 
      epoxide hydrolase (sEH) is an important enzyme that metabolizes the bioactive 
      epoxy fatty acids (EFAs) in the arachidonic acid signaling pathway and converts 
      them to vicinal diols, which appear to be pro-inflammatory. Inhibition of sEH 
      hence offers a mechanism to increase in vivo epoxyeicosanoid levels and resolve 
      pro-inflammatory pathways in disease states. Significant efforts in the field 
      have led to potent single target as well as multi-target inhibitors with 
      promising in vitro and widely encompassing in vivo activities. Successful 
      clinical translation of compounds targeting sEH inhibition will further validate 
      the promised therapeutic potential of this pathway in treating human diseases.
FAU - Iyer, Malliga R
AU  - Iyer MR
AUID- ORCID: 0000-0002-0116-4619
AD  - Section on Medicinal Chemistry, National Institute on Alcohol Abuse and 
      Alcoholism, National Institutes of Health, Rockville, Maryland, United States.
FAU - Kundu, Biswajit
AU  - Kundu B
AD  - Section on Medicinal Chemistry, National Institute on Alcohol Abuse and 
      Alcoholism, National Institutes of Health, Rockville, Maryland, United States.
FAU - Wood, Casey M
AU  - Wood CM
AD  - Section on Medicinal Chemistry, National Institute on Alcohol Abuse and 
      Alcoholism, National Institutes of Health, Rockville, Maryland, United States.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220412
PL  - England
TA  - Expert Opin Ther Pat
JT  - Expert opinion on therapeutic patents
JID - 9516419
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Fatty Acids)
RN  - EC 3.3.2.- (Epoxide Hydrolases)
SB  - IM
MH  - Anti-Inflammatory Agents/pharmacology
MH  - Enzyme Inhibitors/pharmacology/therapeutic use
MH  - *Epoxide Hydrolases
MH  - Fatty Acids
MH  - Humans
MH  - *Patents as Topic
OTO - NOTNLM
OT  - EETs
OT  - enzymatic activity
OT  - hypertension
OT  - inflammatory diseases
OT  - sEH inhibitor
OT  - sEH-P
OT  - soluble epoxide hydrolase
EDAT- 2022/04/13 06:00
MHDA- 2022/05/26 06:00
CRDT- 2022/04/12 05:26
PHST- 2022/04/13 06:00 [pubmed]
PHST- 2022/05/26 06:00 [medline]
PHST- 2022/04/12 05:26 [entrez]
AID - 10.1080/13543776.2022.2054329 [doi]
PST - ppublish
SO  - Expert Opin Ther Pat. 2022 Jun;32(6):629-647. doi: 10.1080/13543776.2022.2054329. 
      Epub 2022 Apr 12.